151 related articles for article (PubMed ID: 33572094)
1. Multifunctional Isosteric Pyridine Analogs-Based 2-Aminothiazole: Design, Synthesis, and Potential Phosphodiesterase-5 Inhibitory Activity.
Hussein AHM; Khames AA; El-Adasy AA; Atalla AA; Abdel-Rady M; Hassan MIA; Abou-Salim MA; Elshaier YAMM; Barakat A
Molecules; 2021 Feb; 26(4):. PubMed ID: 33572094
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
4. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
Kayık G; Tüzün NŞ; Durdagi S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):311-330. PubMed ID: 28150511
[TBL] [Abstract][Full Text] [Related]
5. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach.
Ongaro A; Zagotto G; Memo M; Gianoncelli A; Ribaudo G
Nat Prod Res; 2021 May; 35(10):1648-1653. PubMed ID: 31140295
[TBL] [Abstract][Full Text] [Related]
6. In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.
Kayık G; Tüzün NŞ; Durdagi S
J Biomol Struct Dyn; 2017 Oct; 35(13):2830-2852. PubMed ID: 27581752
[TBL] [Abstract][Full Text] [Related]
7. Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.
Chau Y; Li FS; Levsh O; Weng JK
PLoS One; 2019; 14(9):e0222803. PubMed ID: 31539416
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction.
Hudwekar AD; Kotwal P; Dar MI; Balgotra S; Dogra A; Kour J; Chobe SS; Nandi U; Hussain Syed S; Sawant SD
Chem Biodivers; 2023 Apr; 20(4):e202200707. PubMed ID: 36915218
[TBL] [Abstract][Full Text] [Related]
9. Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice.
Karakhanova S; Yang Y; Link J; Soltek S; von Ahn K; Umansky V; Werner J; Bazhin AV
Mol Immunol; 2013 Dec; 56(4):649-59. PubMed ID: 23911424
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Reddy GL; Dar MI; Hudwekar AD; Mahajan P; Nargotra A; Baba AM; Nandi U; Wazir P; Singh G; Vishwakarma RA; Syed SH; Sawant SD
Bioorg Chem; 2019 Aug; 89():103022. PubMed ID: 31181491
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.
Ahmed NS; Gary BD; Tinsley HN; Piazza GA; Laufer S; Abadi AH
Arch Pharm (Weinheim); 2011 Mar; 344(3):149-57. PubMed ID: 21384413
[TBL] [Abstract][Full Text] [Related]
14. Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil.
Corbin JD; Foster TL; Bessay E; Busch J; Blount M; Francis SH
Cell Signal; 2011 May; 23(5):778-84. PubMed ID: 21187142
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol and sildenafil synergistically improve diabetes-associated erectile dysfunction in streptozotocin-induced diabetic rats.
Bai Y; An R
Life Sci; 2015 Aug; 135():43-8. PubMed ID: 26006044
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of N
Pobsuk N; Paracha TU; Chaichamnong N; Salaloy N; Suphakun P; Hannongbua S; Choowongkomon K; Pekthong D; Chootip K; Ingkaninan K; Gleeson MP
Bioorg Med Chem Lett; 2019 Jan; 29(2):267-270. PubMed ID: 30509781
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Corbin JD; Francis SH; Webb DJ
Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of pyrazolo[3,4-d]pyrimidinone derivatives: Discovery of selective phosphodiesterase-5 inhibitors.
Shaaban MA; Elshaier YAMM; Hammad AH; Farag NA; Hassan Haredy H; AbdEl-Ghany AA; Mohamed KO
Bioorg Med Chem Lett; 2020 Aug; 30(16):127337. PubMed ID: 32631538
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
Zoraghi R; Corbin JD; Francis SH
J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275
[TBL] [Abstract][Full Text] [Related]
20. Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.
Abdel-Halim M; Tinsley H; Keeton AB; Weam M; Atta NH; Hammam MA; Hefnawy A; Hartmann RW; Engel M; Piazza GA; Abadi AH
Bioorg Chem; 2020 Nov; 104():104322. PubMed ID: 33142429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
